Gapping down
In reaction to disappointing earnings/guidance: SCSS -26.4% (also downgraded at Keybanc and Piper), IBM -6.3% (IBM downgraded to Neutral from Buy at UBS), USG -5.6%, RDA -5.3%, XLNX -4.6%, EBAY -4.2%, UNH -2.9%, GS -2.5%, BX -1.9%, DGX -1.7%, FLR -0.9%, EWBC -0.9%.
Select financial related names showing weakness following GS results: BCS -1.8%, MS -1.2%, C -0.7%, BAC -0.4%.
Select tech names lower following IBM results: HPQ -1.2% SI -1% , ORCL -0.7% (acquires Compendium; financial terms not disclosed ), MSFT -0.1%
A few names are lower with XLNX/CY: AMD -2.2%, TXN -0.7%, ARMH -1.8%.
Other news:AMRN -61.3% (Amarin confirms FDA Advisory Commitee voted 9 to 2 against approval of Vascepa for AHCNOR indication), TPX -4% (following SCSS results), MFRM -3.9% (following SCSS results), AMZN -1.3% (on EBAY results), COST -0.7% (disclosed in 10-K it received from DEA subpoenas and administrative inspection warrants concerning the Company's fulfillment of prescriptions ), EXP -0.7% (following USG results),LPX -0.6% (following USG results), CTXS -0.4% ( CEO Mark Templeton to Take Temporary Leave of Absence; David Henshall to Serve as Acting CEO),. .
Analyst comments: ASML -1.7% (downgraded to Neutral from Overweight at HSBC, downgraded to Equal-Weight from Overweight at Morgan Stanley), SWK -1% (downgraded to Equal Weight at Morgan Stanley; downgraded to Underweight from Equal Weight at Barclays), BAC -0.8% (downgraded to Outperform from Strong Buy at Raymond James), CSX -0.6% (downgraded to Market Perform from Outperform at BMO Capital Mkts)